Castle Biosciences (CSTL) FCF Margin (2018 - 2026)

Castle Biosciences has reported FCF Margin for 9 years, with the latest figure at 6.33% in Q2 2026.

• Quarterly FCF Margin fell 708.0% year-over-year to 6.33% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.14% (down 1011.0% YoY) and the FY2025 annual result came in at 8.23%, down 277.0% from the prior year.
• FCF Margin improved to 6.33% in Q2 2026 per CSTL's latest filing, from 41.33% in the prior quarter.
• Over five years, FCF Margin peaked at 22.7% in Q4 2025 and troughed at 81.3% in Q1 2022.
• A 5-year average of 9.53% and a median of 4.04% in 2025 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 14094 bps in 2022, down 12782 bps in 2022.
• Over 5 years, FCF Margin stood at 20.31% in 2022, then surged by 210 bps to 22.37% in 2023, then slipped by 13 bps to 19.46% in 2024, then gained by 17 bps to 22.7% in 2025, then tumbled by 72 bps to 6.33% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 6.33%, 41.33%, and 22.7% for Q2 2026, Q1 2026, and Q4 2025 respectively.